A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regime
- Conditions
- nresectable pancreatic neuroendocrine carcinoma
- Registration Number
- JPRN-UMIN000012752
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1) NET G1 or G2 by WHO 2010 criteria 2) Interstitial pneumonia or plumonary fibrosis 3) Metastasis to the central nervous system 4) Concomitant malignancy within 3 years 5) Active infection (exept for hepatitis B or C viral infection) 6) Active gastrointestinal ulcer 7) Severe or uncontrollable complications, such as cardiovascular impairment, infection, diabetes mellitus, and pulmonary disease 8) Severe mental disorder 9) Continuous administration of steroid or immunosuppressant 10) Prior treatment of mTOR inhibitor 11) Pregnant or lactating women and women of childbearing age who were not using effective contraception 12) Patients who was judged to be inappropriate for this study by each investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Overall survival, time to treatment failure, response rate, disease control rate, adverse events